The Clinical Consortium Award mechanism provides support to develop and enhance collaborations and resources necessary for a network of organizations to rapidly execute phase 2 or phase 2-linked phase 1 (phase 1/2) kidney cancer clinical trials. These trials will include investigations of high-impact, novel therapeutic agents or approaches for the management or treatment of kidney cancer. Applicants are expected to demonstrate a broad understanding of kidney cancer research, including knowledge of the current state of clinical studies and priorities related to kidney cancer, and are encouraged to familiarize themselves with the FY23 KCRP’s Overarching Strategic Goals and Focus Areas and to consider this material when preparing their application. Support from this award is to be directed toward Consortium infrastructure needs rather than direct support of the trials themselves.
The principal goal of the KCRP Clinical Consortium Award is to combine the efforts of leading investigators to bring to market high-impact, novel, therapeutic strategies and interventions to improve patient outcomes and significantly decrease the impact of the disease. To facilitate global investigations, U.S. and international institutions are encouraged to apply. Submissions from institutions with access to patients from high-risk, underserved, and/or military populations (as described in the FY23 KCRP Overarching Strategic Goals and Focus Areas) are especially encouraged.
The FY23 Clinical Consortium Award mechanism will be used to select and fund six Clinical Research Sites and one Coordinating Center. PIs will be required to indicate whether the institution is applying as either the Coordinating Center with a Clinical Research Site or as a Clinical Research Site only. Institutions applying as the Coordinating Center, if not selected for funding, have the option to still be considered as a Clinical Research Site only. The Coordinating Center and Clinical Research Sites will be jointly responsible for proposing, selecting, and conducting phase 2 and phase 1/2 clinical trials focused on kidney cancer therapeutic interventions. The Coordinating Center and Clinical Research Sites funded by the FY23 KCRP Clinical Consortium Award will work with additional Clinical Research Sites that may be funded by the KCRP in future fiscal years.
Deadlines:
• Required Pre-Application Deadline: October 26, 2023
• Application Submission Deadline: November 9, 2023
Clinical Consortium Award applications must address at least one of the FY23 KCRP Focus Areas, as presented below. Selection of the Focus Area(s) is the responsibility of the applicant.
• Conduct basic biology research to better understand etiology and cancer progression, metastatic disease, refractory disease and therapeutic resistance, genetic and environmental risk factors, and the prevention of kidney cancer.
• Identify and develop new strategies for screening, early-stage detection, and accurate diagnosis and prognosis prediction of kidney cancers, with examples including biomarkers and imaging, treatment of early-stage cancers.
• Define the biology of rare kidney cancers and develop treatments to improve outcomes and reduce death.
• Develop novel therapeutic strategies for the treatment of kidney cancer, such as novel drug targets, therapeutic modalities and agents, treatment combinations, and drug delivery systems.
• Identify and implement strategies to improve the quality of life and survivorship for patients.
• Identify and implement strategies to mitigate health disparities, such as access to healthcare, social and cultural factors, environmental factors, and biological contributors.
• Increase research capacity through support and development of research conducted by the next generation of kidney cancer researchers, or patient care in alignment with the FY23 KCRP Overarching Strategic Goals.
Independent investigators with a faculty-level appointment (or equivalent) are eligible. Eligibility is not affected by previous receipt of a KCRP Clinical Consortium Award.
